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Oxidative Stress-Dependent Cyclooxygenase-2-Derived
Prostaglandin F2a Impairs Endothelial Function
in Renovascular Hypertensive Rats
Xiao Yu Tian,1,* Wing Tak Wong,1,2,* Fung Ping Leung,1 Yang Zhang,1 Yi-Xiang Wang,3 Hung Kay Lee,4
Chi Fai Ng,5 Zhen Yu Chen,6 Xiaoqiang Yao,1 Chak Leung Au,1 Chi Wai Lau,1 Paul M. Vanhoutte,7
John P. Cooke,2 and Yu Huang1
Abstract
Aims: The role of endothelium-derived contracting factors (EDCFs) in regulating renovascular function is yet to
be elucidated in renovascular hypertension (RH). The current study investigated whether oxidative stress-
dependent cyclooxygenase (COX)-2-derived prostaglandin F2a (PGF2a) impairs endothelial function in renal
arteries of renovascular hypertensive rats (RHR). Results: Renal hypertension was induced in rats by renal artery
stenosis of both kidneys using the 2-kidney 2-clip model. Acute treatment with reactive oxygen species (ROS)
scavengers, COX-2 inhibitors, and thromboxane-prostanoid receptor antagonists, but not COX-1 inhibitors,
improved endothelium-dependent relaxations and eliminated endothelium-dependent contractions in RHR
renal arteries. Five weeks of treatment with celecoxib or tempol reduced blood pressure, increased renal blood
flow, and restored endothelial function in RHRs. Increased ROS production in RHR arteries was inhibited by
ROS scavengers, but unaffected by COX-2 inhibitors; whereas increased PGF2a release was reduced by both ROS
scavengers and COX-2 inhibitors. ROS also induced COX-2-dependent contraction in RHR renal arteries, which
was accompanied by the release of COX-2-derived PGF2a. Further, chronic tempol treatment reduced COX-2 and
BMP4 upregulation, p38MAPK phosphorylation, and the nitrotyrosine level in RHR renal arteries. Conclusion:
These findings demonstrate the functional importance of oxidative stress, which serves as an initiator of in-
creased COX-2 activity, and that COX-2-derived PGF2a plays an important role in mediating endothelial dys-
function in RH. Innovation: The current study, thus, suggests that drugs targeting oxidative stress-dependent
COX-2-derived PGF2amay be useful in the prevention andmanagement of RH .Antioxid. Redox Signal. 16, 363–373.
Introduction
Renal artery stenosis is the major cause of renovascularhypertension (RH) and can lead to reduced renal blood
flow and end-stage renal damage (36). The role of renal vas-
culature in RH was established by Goldblatt et al. (15), who
demonstrated that partial obstruction of the renal artery in-
creased mean arterial pressure, which has the features of RH
in humans. The mechanisms responsible for the development
of RH remain largely undefined, but oxidative stress plays an
important role (12, 26). Nevertheless, it is unclear how oxi-
dative stress affects renovascular function in RH.
Innovation
Endothelium-derived contracting factors (EDCFs) par-
ticipate in the development and maintenance of hyper-
tension. This research reported the functional importance
of cyclooxygenase (COX)-2 derived prostaglandin F2a in
response to oxidative stress as the major EDCF to impair
endothelium-dependent relaxation and enhance endothe-
lium-dependent contraction in renal arteries of renal hy-
pertension induced by renal artery stenosis. Antioxidant or
COX-2 inhibition can reduce blood pressure and improve
endothelial function in renal hypertensive rats.
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Endothelial cell function reflects the condition of vascular
health and predicts the severity of future vascular complica-
tions (37). Impaired endothelium-dependent relaxations
(EDRs) have been reported in aortae (4, 28), superior mesen-
teric arteries (35), and mesenteric resistance arteries (7, 10)
in renovascular hypertensive rats (RHRs). However, little
is known about the impact of RH on vascular reactivity of
renal arteries and renal blood flow. The mechanisms re-
sponsible for reduced EDRs may include activation of the
renin-angiotensin-aldosterone system (20, 26), and over-
production of superoxide derived from the nicotinamide ad-
enine dinucleotide phosphate (NADPH) oxidase (19, 21, 23).
In contrast, no study has been directed toward exploring
the possible effect of RH on endothelium-dependent con-
tractions (EDCs). The endothelium-derived contracting fac-
tors (EDCFs) that contribute to endothelial dysfunction are
reported to be either cyclooxygenase (COX)-mediated ara-
chidonic acid-derived prostaglandins (2, 13) or reactive oxy-
gen species (ROS) (44), which act on vascular smooth muscle
to cause contractions.
Earlier studies showed that selective COX-1 inhibitors
prevent acetylcholine-induced EDCs in aortae of spontane-
ously hypertensive rats (SHRs) (44) and improve EDRs in
mesenteric arteries in angiotensin II-infused mice (39), thus
suggesting that COX-1-derived EDCFs impair endothelial
function. More recently, COX-2-derived constricting prosta-
noids have been suggested to attenuate EDRs in SHR mes-
enteric arteries (40). Indeed, COX-2 inhibitors improve
endothelial function in patients with hypertension and coro-
nary heart disease (5, 41). Nevertheless, whether COX-
derived prostaglandins contribute to endothelial dysfunction
in RH has not been examined.
Although COX-derived prostaglandins and ROS are sug-
gested to be EDCFs, it remains unclear whether ROS can
stimulate endothelial COX isoforms to release EDCFs in renal
arteries of RHRs. The role of EDCFs in regulating renovas-
cular function and renal blood flow in vivo is yet to be eluci-
dated in RH. Therefore, the current study aims at determining
whether ROS regulate COX-derived prostaglandins to cause
endothelial dysfunction in RH.
Results
COX-2 mediates impairments in EDRs
in renal arteries of RHRs
Acetylcholine-induced EDRs were blunted in renal arteries
from RHRs 5 weeks after the induction of renal artery stenosis
and further reduced 10 weeks after surgery compared with
those from sham-operated rats (Fig. 1A, B). Renal arteries
from RHRs exhibited a biphasic response to acetylcholine,
with an initial relaxation followed by a contraction at con-
centrations of acetylcholine higher than 1lM (Fig. 1A, B).
Endothelium-independent relaxations in response to sodium
nitroprusside (SNP) (Fig. 1C) or to nitroglycerin (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertonline.com/ars) were similar between the two
groups. Thirty minutes of treatment of RHR renal arteries
with the nonselective COX inhibitor indomethacin (Fig. 1E),
COX-2 inhibitors celecoxib, NS398, DuP697, or the throm-
boxane prostanoid (TP) receptor antagonist S18886 restored
the impaired EDRs (Fig. 1D, F); whereas COX-1 inhibitors SC-
560 and valeryl salicylate (VAS) had no effect (Fig. 1E). The
protein synthesis inhibitor cycloheximide did not modify
EDRs in renal arteries (Fig. 1G).
COX-2 mediates EDCs in renal arteries of RHRs
Acetylcholine elicited EDCs in renal arteries from RHRs (5
and 10weeks after surgery) comparedwith those from control
rats (Fig. 2A, B). Acetylcholine-induced EDCs were only ob-
served in the presence of NG-nitro-L-arginine methyl ester (L-
NAME) in rings with endothelium (Supplementary Fig. S2).
Indomethacin (Fig. 2C), celecoxib, DuP 697 orNS398 (Fig. 2C),
or S18886 (Fig. 2D) abolished EDCs; whereas SC-560, VAS
(Fig. 2E), or cycloheximide (Fig. 2F) had no effect.
Chronic celecoxib or tempol treatment increases renal
blood flow, reduces blood pressure, and improves
endothelial function in RHRs
Renal blood flow was measured by magnetic resonance
image (MRI) in the renal cortex, which was selected as the
region of interest for the intensity analysis of Gd-DOTA-in-
duced signal enhancement. The maximum intensity was ob-
served in the aorta first, followed by the renal cortex *20 s
after bolus injection of Gd-DOTA into the tail vein, then the
outer and inner medulla, and finally, the renal pelvis. Renal
blood flow assessed by cortical signal enhancement (Fig. 3A)
was reduced in RHRs compared with control rats. The re-
duced flow was restored after treatment with celecoxib or
tempol (Fig. 3B, C), accompanied by a reduction in systolic
blood pressure in RHRs; whereas celecoxib or tempol treat-
ment did not affect the blood pressure of control rats (Fig. 3D).
After drug treatment, EDRs of RHR renal arteries were im-
proved (Fig. 3E), and EDCs were reduced (Fig. 3F). Acute
exposure to the putative NADPH oxidase inhibitor apocynin
improved EDRs in RHR renal arteries but did not cause fur-
ther improvement in celecoxib-treated RHRs (Supplementary
Fig. S3).
ROS trigger COX-2-dependent endothelial dysfunction
in renal arteries of RHRs
Tiron plus DETCA, or tempol (ROS scavengers) aug-
mented EDRs (Fig. 4A) and abolished EDCs (Fig. 4B) in re-
nal arteries from RHRs, which were unaffected by the
xanthine oxidase inhibitor, allopurinol (Supplementary
Fig. S4). Electron paramagnetic resonance (EPR) spectra
showed an increased generation of superoxide anions (O2
 - )
in RHR renal arteries on acetylcholine stimulation in the
presence of L-NAME (Fig. 4C, D). Renal arteries from tempol-
treated RHRs but not from celecoxib-treated RHRs showed a
reduction of ROS generation (Fig. 4C, D). Further, H2O2
- (Fig.
4E) and hypoxanthine + xanthine oxidase (HX-XO)-induced
contractions (Fig. 4F) in RHR renal arteries (3.43 – 0.56mN/
mm for H2O2 and 2.87 – 0.66mN/mm for HX-XO) were
greater than those of control rats (1.09 – 0.13mN/mm for
H2O2 and 0.11 – 0.03mN/mm for HX-XO). Both Celecoxib
and S18886 prevented H2O2- or HX-XO-induced responses;
whereas SC-560 did not (Fig. 4E, F). Removal of the endo-
thelium reduced contractions elicited by H2O2 or HX-XO
(Fig. 4E, F). A 4-h period of treatment with H2O2 or HX-XO
increased COX-2 expression in renal arteries and in pri-
mary aortic endothelial cells from control rats (Supplemen-
tary Fig. S5).
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COX-2-derived prostaglandin F2a mediates endothelial
dysfunction in renal arteries of RHRs
The amount of prostaglandin F2a (PGF2a) (Fig. 5A), 8-
isoprostane (Fig. 5B), 6-keto PGF1a (metabolites of prostacy-
clin [PGI2], Fig. 5C), PGE2 (Supplementary Fig. S6a), PGD2
(Supplementary Fig. S6b), and TXB2 (metabolites of TXA2,
Supplementary Fig. S6c) released in response to acetylcholine
(100 lM) stimulation was greater in RHR than in control
rat renal arteries. Chronic treatment with celecoxib or
tempol inhibited acetylcholine-stimulated release of PGF2a, 8-
isoprostane, PGE2, and PGD2 but not 6-keto PGF1a and TXB2
(Fig. 5A–C and Supplementary Fig. S5). A 30-min exposure to
celecoxib or tiron plus DETCA inhibited the acetylcholine-
stimulated release of all six prostaglandins (Fig. 5A–C and
Supplementary Fig. S6), whereas SC-560 reduced PGE2,
PGD2, and TXB2 (Supplementary Fig. S5) without affecting
PGF2a, 8-isoprostane, and 6-keto PGF1a.
PGF2a and 8-isoprostane produced greater contractions in
renal arteries of RHRs than in control arteries (Fig. 5D, E),
whereas PGI2 produced comparable responses in both groups
(Fig. 5F). When PGF2a was administered to RHR renal artery
preparations at a concentration (*38 nM) comparable to the
value measured by enzyme immunoassay (EIA) in acetyl-
choline-stimulated RHR renal arteries, the induced contrac-
tions were similar inmagnitude to EDCs (Fig. 5D). In contrast,
the EIA-detected amounts of 8-isoprostane at 2.12 nM and
PGI2 at 0.38 lM did not cause contraction (Fig. 5E, F). In ad-
dition, H2O2 at 100 lM increased the release of PGF2a from
RHR renal arteries, which was reduced by celecoxib but not
SC-560 (Fig. 5G). Plasma PGF2a concentration was also de-
creased after chronic celecoxib or tempol administration to
RHRs (Fig. 5H). Further, a 30-min exposure to 7 nM PGF2a
reduced EDRs in renal arteries from control rats, which was
prevented by pretreatment with S18886 (0.1 lM) but not with
celecoxib (3 lM) (Fig. 5I).
Increased expression of COX-2 and oxidative stress
biomarker proteins in renal arteries of RHRs
The levels of 3-nitrotyrosine (Fig. 6A), COX-2 (Fig. 6B),
BMP4 (Fig. 6C), and the phosphorylated form of p38MAPK
(Fig. 6D)were significantly increased in renal arteries of RHRs
compared with those from control rats. Multiple bands of
FIG. 1. Cyclooxygenase (COX)-2 medi-
ates the impairment of endothelium-
dependent relaxations (EDRs) in renal
arteries of renovascular hypertensive rats
(RHRs). (A) Representative traces show-
ing blunted acetylcholine (ACh)-induced
EDRs of renal arteries from RHRs com-
pared with those from control rats. (B)
Concentration-response curves for ACh-
induced EDRs in renal arteries from RHRs
5 and 10 weeks after surgery and control
rats. (C) Endothelium-independent relax-
ations induced by sodium nitroprusside
(SNP) in renal arteries were comparable in
RHRs and control rats. Effects of 30-min
exposure to (D) COX-2 inhibitors cel-
ecoxib, DuP697, or NS398 (3 lM in each
case); (E) COX-1 inhibitors SC-560
(0.3 lM), valeryl salicylate (VAS, 0.3mM),
or nonselective COX inhibitor indometh-
acin (1lM); (F) thromboxane prostanoid
(TP)-receptor antagonist S18886 (0.1 lM);
and (G) protein synthesis inhibitor cyclo-
heximide (10 lM) on EDRs in RHR renal
arteries. Results are mean – standard error
of the mean (SEM) of six to eight experi-
ments. *p < 0.05 versus control in each
panel.
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nitrotyrosine at*60, 55, 40, and 35 kDawere detected in renal
arteries (Fig. 6A). Chronic treatment with tempol but
not celecoxib inhibited the up-regulation of 3-nitrotyrosine,
COX-2, BMP4, and p38 phosphorylation in RHR renal ar-
teries. In contrast, the protein levels of COX-1 (Fig. 6B) and
NOX2 (Fig. 6F)were similar among all groups. The expression
of p67phox (Fig. 6E) was increased in renal arteries from RHR
but remained unaffected after celecoxib or tempol treatment
(Fig. 6E).
Discussion
The current study provides evidence for a crucial role of
ROS-dependent COX-2-derived PGF2a in endothelial dys-
function in RH. The major findings are as follows: (i) the im-
paired EDRs and the augmented EDCs in renal arteries of
RHRs are restored by treatment with COX-2 inhibitors, TP
receptor antagonists and ROS scavengers; (ii) chronic treat-
ment with celecoxib or tempol increases renal blood flow,
reduces blood pressure, and improves endothelial function in
RHRs; and (iii) ROS are a prerequisite for the occurrence of
endothelial dysfunction through the generation of COX-2-
derived PGF2a, suggesting that ROS activates COX-2 to re-
lease PGF2a, which impairs EDRs and induces EDCs in RHR
renal arteries.
ROS contribute to the development of endothelial dys-
function in renal vasculature during the development of RH.
We showed that reduced EDRs in RHR renal arteries
were reversed by ROS scavengers, under both in vitro and
in vivo conditions. In addition, the p67phox level increased, and
NADPH oxidase inhibitor apocynin improved EDRs in RHR
renal arteries (Supplementary Fig. S2). ROS production from
NADPH oxidase is a major source of oxidative stress in en-
dothelial dysfunction associatedwith hypertension (17, 18, 23,
30). In aortae of renovascular hypertensive mice, the blunted
EDRs were prevented by genetic deletion of the NADPH
oxidase subunit gp91phox (23). Recent studies also demon-
strated that antioxidant treatment is able to lower blood
pressure and improve EDRs in RHRs (4). The current results
show that tempol treatment improved EDRs in renal arteries,
reduced blood pressure (Supplementary Fig. S7), and in-
creased renal blood flow in vivo in RHRs.
An earlier report indicated that nonselective COX inhibi-
tion normalizes the blunted EDRs in small mesenteric arteries
in RHRs (10). To the best of our knowledge, there is no report
about the potential impact of RH on EDC responses. The
current study demonstrates that COX-2, rather than COX-1, is
the key enzyme mediating the effect that reduces EDRs
and augments EDC in RHR renal arteries. In addition, up-
regulation of COX-2 rather than COX-1 was observed in RHR
renal arteries. It was reported that COX-1, rather than COX-2,
mediates EDCs in aortae from SHR (45). However, COX-2-
derived constricting prostanoids have been recently sug-
gested to impair EDRs in mesenteric arteries of SHR (40).
Taken together, these observations suggest that there could be
a significant difference in the involvement of COX isoforms
depending on the etiology of hypertension and/or the specific
vascular bed chosen for examination.
FIG. 2. COX-2 mediates endothelium-
dependent contractions (EDCs) in renal
arteries of RHRs. (A) Representative
traces showing the augmented ACh-
induced EDCs in RHR renal arteries. (B)
Concentration-response curves for ACh-
induced EDCs in the presence of NG-
nitro-L-arginine methyl ester (L-NAME) 5
and 10 weeks after surgery in RHRs and
control rats. Effect of 30-min exposures to
(C) indomethacin (1 lM), celecoxib,
DuP697, and NS398 (3lM in each case);
(D) S18886 (0.1 lM); (E) VAS (0.3mM)
and SC-560 (0.3 lM); and (F) cyclohexi-
mide (10 lM) on EDCs in RHR renal ar-
teries. Results are mean– SEM of six to
eight experiments. *p < 0.05 versus control
in each panel.
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ROS might function as EDCFs in the canine basilar artery
(25), and ROS facilitated EDC in aortae of SHR (45). In addi-
tion, COX-derived prostaglandins were suggested to be one
major source of EDCF apart from superoxide anions (1, 14, 39,
46). The current study indicates that EDCFs derived from
COX-2were released in response to ROS stimulation based on
the following findings. First, ROS scavengers prevented
EDCs. Second, acetylcholine-stimulated ROS production was
greater in RHR renal arteries and ROS-generating agents,
such as H2O2 and HX-XO, could elicit celecoxib-inhibitable
contractions and upregulate COX-2 expression. Moreover,
the increase in peroxynitrite-induced protein nitration (48)
observed in RHR renal arteries was inhibited after tempol
treatment but was unaffected by celecoxib. On the basis of our
previous report, it is worth noting that ROS is also an up-
stream regulator of COX-2 expression and activity that in-
duces endothelial dysfunction in mouse arteries (42).
The current study shows that BMP4, an upstreammediator
of endothelial dysfunction, was upregulated in RHR renal
arteries, which is consistent with our previous finding of in-
creased BMP4 expression in renal arteries from patients with
hypertension and SHRs (42). Of importance, treatment with
the antioxidant tempol but not celecoxib inhibited BMP4 up-
regulation. Although BMP4 is an upstream regulator of the
expression of pro-inflammatory genes in endothelial cells in
response to oxidative stress (29, 31, 33), BMP4 expression can
FIG. 3. Chronic celecoxib or tempol treatment increases renal blood flow, reduces blood pressure and improves en-
dothelial function in RHRs. (A) Representative illustration showing the maximal signal enhancement in the renal cortex
after a tail vein injection of Gd-DOTA as measured by magnetic resonance image. Upper panel: colored image; lower panel:
black and white image of the same specimen. (B, C) Summarized data showing the relative signal change compared with the
time point before the signal intensity increases. (D) Systolic blood pressure measured by a tail-cuff method in tempol- or
celecoxib-treated RHRs and control rats. Concentration-response curves for ACh-induced EDRs (E) and EDCs in the presence
of L-NAME (F) in renal arteries from control rats, RHRs, and RHRs treated with celecoxib or tempol. Results are mean – SEM
of six to eight experiments. *p < 0.05 versus control, #p< 0.05 versus RHR. (To see this illustration in color the reader is referred
to the Web version of this article at www.liebertonline.com/ars).
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also be regulated by oxidative stress (6, 33). We also found
that p38 phosphorylation in RHR renal arteries was reduced
after tempol treatment, thus suggesting that p38was involved
in ROS-induced endothelial dysfunction in RHRs (42).
The current study extends the understanding of arachi-
donic acid derivatives as EDCFs, which was supported by
measurements of prostaglandin release by EIA and use of
exogenously applied prostaglandins to induce vasoconstric-
tion. The EIA results showed increased release of all types of
prostaglandins in RHR renal arteries in response to acetyl-
choline, whereas only PGF2a, 6-keto PGF1a (the stable me-
tabolite of PGI2), and 8-isoprostane were indicated to be COX-
2-derived EDCF candidates. To verify this, exogenous PGI2,
PGF2a, or 8-isoprostane were applied to determine whether
they caused contractions in renal arteries. Only PGF2a pro-
duced contraction at a concentration near to that determined
by EIA upon acetylcholine stimulation. Although 8-iso-
prostane and PGI2 contracted renal arteries, the threshold
concentration for both prostaglandins to evoke contraction
was much higher than that detected by EIA in response to
acetylcholine. The involvement of PGD2, PGE2, or TXA2 was
unlikely, because their release was prevented by COX-1 in-
hibitors that did not block EDCs. These results support the
conclusion that PGF2a is the most likely EDCF in RHR renal
arteries. Previous studies on oxidative stress-dependent COX-
2 induction were mainly focused on endothelial cell inflam-
mation and apoptosis, and PGE2 was considered the major
contributor to the effect of COX-2 induction (3, 8, 24, 34).
However, PGF2a was less studied (3, 22). The current study
provides new information about the critical role of COX-2 and
PGF2a in renal vascular hypertension. It is also noted that the
pathological role of PGF2a has been recently revealed, as this
prostaglandin increases blood pressure and promotes athero-
genesis in mice (47). The current results also show that COX-2
inhibition, either in vivo or ex vivo, can reduce the production of
the PGI2metabolite 6-keto-PGF1a, which is unaffected byCOX-
1 inhibitors, thus suggesting that COX-2 is the major enzyme
responsible for PGI2 synthesis in renal vasculature. This finding
is different from that of a previous study concluding that COX-
1 is the major enzyme of PGI2 synthesis (9). The relative im-
portance of COX-2-derived PGI2 in the development of renal
hypertension is yet to be examined.
The current study also shows that ROS do not cause con-
traction directly in RHR renal arteries. A more likely expla-
nation is that the increased production of ROS stimulates
endothelial COX-2 to release PGF2a, which activates TP re-
ceptors to cause contraction of vascular smooth muscle cells
under renovascular hypertensive conditions. This was sup-
ported by the following observations: (i) Exogenous ROS
(H2O2 or HX-XO) produced greater contractions in renal ar-
teries from RHRs than control; (ii) ROS-induced contractions
were abolished by celecoxib and S18886; (iii) ROS-induced
contractions were reduced in arteries without endothelium;
(iv) H2O2 stimulated PGF2a release was prevented by cel-
ecoxib; (v) The acetylcholine-stimulated release of PGF2a was
inhibited by ROS scavengers in RHR arteries; (vi) PGF2a at-
tenuated EDRs in renal arteries from control rats, which was
prevented by S18886 but not by a COX-2 inhibitor. Moreover,
chronic treatment with tempol, but not celecoxib, attenuated
the up-regulation of both nitrotyrosine and COX-2 in RHR
FIG. 4. Reactive oxygen species (ROS)
triggers COX-2-dependent endothelial
dysfunction in RHRs. Effects of 30-min
exposure to tiron (1mM) plus DETCA
(100lM), or tempol (100lM) on EDRs (A)
and EDCs (B) in RHR renal arteries. (C)
Electron paramagnetic resonance (EPR)
spectroscopy showing markedly increased
amplitude of ROS signal in response to
ACh (100lM) in RHR renal arteries. (D)
Summarized data for EPR signal inten-
sity. Effects of SC-560 (0.3lM), celecoxib
(3lM), S18886 (0.1lM), and endothelium
removal on contractions evoked by H2O2
(100lM) (E) and HX-XO (100lM hypo-
xanthine plus 0.01 units/ml xanthine oxi-
dase (F) in RHR renal arteries. Results are
mean– SEM of four to six experiments.
*p< 0.05 versus control #p< 0.05 versus
RHR. –E, without endothelium.
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arteries. Taken together, the current results support the role of
ROS as a trigger in the acetylcholine-stimulated release of
endothelial COX-2-derived PGF2a in RHR renal arteries.
However, there are other potential factors that might also be
involved in the enhanced contraction in RHR renal arteries
including diminished nitric oxide (NO) production, oxidative
stress per se, and angiotensin II (11, 32).
In summary, the current study demonstrates that both
celecoxib and tempol reduce blood pressure, increase renal
blood flow, and improve endothelial function in RHRs. In
RHR renal arteries, ROS is the initiator that activates endo-
thelial COX-2 to release PGF2a, the most likely EDCF to par-
ticipate in endothelial dysfunction in RHRs. Drugs targeting
this ROS-COX-TP cascade may be useful in the prevention
and management of RH.
Materials and Methods
Chemicals
Cycloheximide was purchased from Calbiochem, EMD
Biosciences. VAS, PGF2a and PGI2 were from Cayman
Chemical. Indomethacin, 5-bromo-2-(4-fluorophenyl)-3-[4-
(methylsulfonyl)phenyl]-thiophene (DuP-697) and N-[2-(cy-
clohexyloxy)-4-nitrophenyl]-methanesulfonamide (NS-398),
indomethacin, and 8-isoprostane were from Tocris (Avon-
mouth). SC-560 and 3-[(6-amino-(4-chlorobenzensulphonyl)-
2-methyl-5,6,7,8-tetrahydronapht]-1-yl) propionic acid (S18886)
were kind gifts from Institut de Recherches Servier. Ni-
troglycerin was from Schwarz Pharma. All others were pur-
chased from Sigma-Aldrich Chemical Co. Acetylcholine, L-
NAME, phenylephrine, SNP, nitroglycerin, PGI2, tiron, and
tempol were prepared in distilled water; all other drugs were
dissolved in dimethylsulfoxide (Sigma-Aldrich).
Induction of RH and drug treatment
The experimental protocol approved by the institutional
animal care and use committee was consistent with the Guide
for the Care and Use of Laboratory Animals published by the
National Institutes of Health. RH was induced by a surgical
bilateral renal artery stenosis procedure in male Sprague-
Dawley rats. The rats (80–100 g) were anaesthetized with
ketamine (35mg kg- 1) plus xylazine (7mg kg- 1). After per-
forming a midline laparotomy, renal arteries of both kidneys
were carefully separated from adjacent adhering tissue and
then individually occluded by a silver clip (internal diameter:
0.2mm). Sham-operated rats (Control) were subjected to
laparotomy and renal artery separation only. All rats had free
access to rat chow and tapwater, andweremaintained in their
cages in a controlled environment at 23C– 1C with a 12-h
dark/light cycle. Five weeks later, RHRs with systolic blood
pressure over 180mmHg were randomly divided into three
groups: RHRs receiving vehicle (RHR); RHRs receiving orally
administered celecoxib at a dose of 10mg.kg - 1.day- 1 for 5
weeks (RHR +Celecoxib); or RHRs receiving tempol (RHR +
FIG. 5. COX-2 derived
prostaglandin F2a (PGF2a)
mediates endothelial dys-
function in renal arteries of
RHRs. Acetylcholine (100lM)-
stimulated release of PGF2a
(A), 8-isoprostane (B), and
6-keto PGF1a (prostacyclin
[PGI2]) (C) in control rats,
RHRs, and RHRs treated
with celecoxib or tempol.
Contractions induced by
PGF2a (D), 8-isoprostane (E),
and PGI2 (F) in renal arteries
of RHRs and control rats.
(G) Effects of celecoxib and
SC-560 on H2O2 (100 lM)-
stimulated released of PGF2a
in renal arteries. (H) Plasma
concentration of PGF2a in
control rats, RHRs, and RHRs
treated with celecoxib or
tempol. (I) Effects of celecox-
ib and S18886 on PGF2a-
induced reduction of EDRs in
renal arteries from control
rats. Results are mean – SEM
of four to eight experiments.
*p < 0.05 versus control (SD),
#p< 0.05 versus RHR.
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Tempol) at a dose of 10mg.kg-1.day-1 for 5 weeks. Some
sham-operated control rats were also orally treated with
10mg.kg-1.day-1 celecoxib (Control+Celecoxib) or 10mg.kg-1.
day-1 tempol (Control+Tempol). Systolic blood pressure was
measured by a tail-cuff method.
Vascular reactivity
Vasoreactivity of the interlobar renal arteries were mea-
sured as described (27). The effects of various compounds on
EDRs and EDCs were tested. The EDRs occurred in response
to the cumulative addition (0.01–30 lM) of acetylcholine in
arteries that had been precontracted by phenylephrine (1 lM),
and the EDCswere elicited by acetylcholine (0.1–100lM) after
pretreatment with 100 lM L-NAME, which was used to
eliminate the interference of endothelium-derived NO. These
effects were tested using 30-min incubations with the fol-
lowing compounds: SC-560 (0.3 lM; COX-1 inhibitor); VAS
(300 lM; COX-1 inhibitor); celecoxib, NS398, DuP697 (3 lM;
COX-2 inhibitor); indomethacin (1lM; nonselective COX
FIG. 6. Protein expression
in renal arteries of RHRs.
Western blots showing the
expression of (A) 3-nitrotyr-
osine (60, 55, 40, and 35 kDa);
(B) COX-2 (72 kDa) and COX-
1 (72kDa); (C) BMP4 (36kDa);
(D) phospho-p38MAPK and
total p38MAPK (43kDa); (E)
p67phox (67kDa); and (F)
NOX2 (67kDa) in renal ar-
teries from control rats, RHRs,
and RHRs treated with cel-
ecoxib or tempol. GAPDH
(37kDa) was used as a house-
keeping protein. Results rep-
resent mean– SEM of four ex-
periments. *p< 0.05 versus
control, #p<0.05 versus RHR.
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inhibitor); tiron [1mM; superoxide dismutase mimetic] plus
diethyldithiocarbamate acid [DETCA, 100 lM; hydroxyl
radical (HO) scavenger]; tempol (100 lM); apocynin (100 lM,
NADPH oxidase inhibitor); allopurinol (100 lM xanthine ox-
idase inhibitor); S18886 (0.1 lM; thromboxane receptor an-
tagonist); and cycloheximide (10 lM, protein synthesis
inhibitor) (45). Endothelium-independent relaxations to SNP
or nitroglycerinwere studied in arterieswithout endothelium.
Hydrogen peroxide (H2O2, 100lM), PGF2a, 8-isoprostane,
PGI2, and a combination of hypoxanthine (HX, 100 lM) and
xanthine oxidase (XO, 0.01 unit/ml), were used to induce
contraction in the presence of 100lM L-NAME.
EPR spectroscopy
The formation of ROS was measured by a reaction with the
spin trap agent TEMPONE-H using EPR spectroscopy in rat
renal arteries. The detailed method is included in the Sup-
plementary Materials.
Measurement of prostaglandins by EIA
The amounts of individual prostaglandins were measured
with EIA kits (Cayman Chemical) in rat renal arteries. The
detailed method is included in the Supplementary Materials.
Measurement of renal blood flow by MRI acquisition
MRI studies were performed using a 3 T clinical whole-
body imaging system (Achieva; Philips Healthcare) as pre-
viously described (16). The detailed method is presented in
the Supplementary Materials.
Protein extraction and western blotting
Renal arteries were isolated and frozen in liquid nitrogen
and homogenized in RIPA lysis buffer. Proteins were ex-
tracted from the vessels as previously described (43). Western
blot analyses were performed with appropriate specific pri-
mary antibodies including COX-2 or COX-1 (1:1000; Cayman
Chemical), 3-nitrotyrosine (1:1000; Upstate Biotechnology),
BMP4 (1:1000; Sigma), phospho- and total p38MAPK, p67phox
(1:1000; Cell Signaling), and NOX2 (1:1000; Abcam).
Data analysis
Results are given as mean– standard error of the mean of n
experiments in arteries from different rats. Contractions are
expressed as active tension (force recorded/[2 · length of
ring]) (38). Western blots were analyzed using Quantity One
(Bio-Rad). The protein expression is normalized to the level of
GAPDH and is expressed relative to the control. Student’s t-
test was used for statistical comparison between two groups,
whereas ANOVA was used for comparisons involving more
than two groups. The concentration-response curves were
analyzed by one-way ANOVA followed by Bonferroni’s post
hoc test. Probability values of less than 0.05 indicate statisti-
cally significant differences between treatments.
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Abbreviations Used
ACh¼ acetylcholine
COX¼ cyclooxygenase
DTPA¼diethylenetriaminepentaacetic acid
EDC¼ endothelium-dependent contraction
EDCF¼ endothelium-derived contracting factor
EDR¼ endothelium-dependent relaxation
EIA¼ enzyme immunoassay
EPR¼ electron paramagnetic resonance
HX-XO¼hypoxanthine+xanthine oxidase
L-NAME¼NG-nitro-L-arginine methyl ester
NADPH¼nicotinamide adenine dinucleotide
phosphate
MRI¼magnetic resonance image
NO¼nitric oxide
PGF2a¼prostaglandin F2a
PGI2¼prostacyclin
RHR¼ renovascular hypertensive rat
ROI¼ region of interest
ROS¼ reactive oxygen species
SEM¼ standard error of the mean
SHR¼ spontaneously hypertensive rat
SNP¼ sodium nitroprusside
TE¼ time to echo
TP¼ thromboxane prostanoid
TR¼ repetition time
VAS¼valeryl salicylate
3D¼ three-dimensional
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